B. Thürlimann

Type de document

Articles (4) Colloques et conférences (2)

Co-auteur

Date

Source

Mot-clé

procès (6) Breast (6) thérapie (5) cancer (5) Treatment (5) Cancer (5) Therapeutics (5) Patients (5) Cancer (5) Patients (5) maladie (4) survie (4) Methods (4) Survival (4) Manufacturers' agents (4) Human beings (4) Commission merchants (4) Older people (4) Methods (4) maladie (4) temps (durée) (3) Chemotherapy (3) Time (3) Swiss (3) Months (3) Expression (3) Chemotherapy (3) Cancer--Patients (3) test (2) risque (2)

Documents écrit par B. Thürlimann (6) | parle de B. Thürlimann (0)

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.
S. Schmid et al. (10 sept. 2019)
Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07).
K. Zaman et al. (2012)
Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue.
J. Antonov et al. (2010)
MMP-9 as predictive factor for response and progression free survival in breast cancer patients treated with bevacizumab and pegylated liposomal doxorubicin. A multicenter, single-arm phase II trial (SAKK24/06). On behalf of the Swiss Group for Clinical Cancer Research (SAKK).
K. Zaman et al. (2010)
hMMP9 as predictive factor for response and progression free survival in breast cancer patients treated with bevacizumab and pegylated liposomal doxorubicin (PLD)
K. Zaman et al. (2010)
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).
L. Perey et al. (2007)